Tag: Healthcare

  • Proprio: Seattle AI Profile — Product, Footprint & Verified Record

    Proprio: Seattle AI Profile — Product, Footprint & Verified Record

    Washington AI Companies Census · Verified Record (November 19, 2026)
    Sourced Baseline: As of November 19, 2026, Proprio operates actively from its Seattle headquarters as a clinical-stage and commercial surgical navigation company spun out of the University of Washington. Its Paradigm platform combines light-field imaging, computer vision, and surgical AI models to guide spine procedures without repeated intraoperative radiation, backed by $75M–$84M in reported funding and a 50-person team listed on the Fall 2026 GeekWire 200.
    PROFILE BRIEF · HOUSE PDF & MARKDOWN TWIN
    Proprio — Seattle AI Profile
    Download the formatted 2-page profile brief (PDF) or open the single-source Markdown twin for Proprio. Every claim below links to its verified primary source.

    What Proprio Builds

    Proprio develops Paradigm, an FDA-cleared, radiation-free surgical navigation and data intelligence system detailed on the Proprio website. Paradigm integrates light-field imaging, multi-camera computer vision, advanced sensors, and an AI foundation model built for surgery to continuously track anatomy at the segmental level in real time.

    Instead of relying on repeated intraoperative CT scans or X-ray fluoroscopy to verify instrument and bone positions, Paradigm renders dynamic 3D surgical models and provides on-demand intraoperative measurements of spinal alignment, disc height, and segmental angles. As covered by GeekWire in 2023 and April 2025, the system aims to cut radiation exposure and workflow interruptions in complex spine and neurosurgery operating rooms.

    Beyond real-time guidance, Paradigm passively records structured intraoperative data during every procedure. Proprio positions this dataset—which its website states draws contributions from hundreds of surgeons—to support institutional learning, clinical training, and surgical safety programs.

    • Radiation-free 3D navigation: Combines light-field imaging, computer vision, and sensor fusion to render dynamic 3D surgical views without repeated CT or X-ray scans.
    • Real-time intraoperative metrics: Delivers on-demand measurements of spinal alignment, disc height, and segmental angles while tracking anatomy continuously.
    • Surgical AI foundation model: Uses an AI foundation model informed by hundreds of contributing surgeons, paired with passive intraoperative data capture.
    • Iterative FDA 510(k) milestones: Received its second major FDA 510(k) clearance in April 2025 for real-time measurements and announces a third major 510(k) clearance on its live site for 3D dynamic segmental viewing.
    Proprio — Verified Washington AI Snapshot
    Verified profile snapshot for Proprio (Seattle, WA) as of November 19, 2026.
    FieldVerified Record (As of Nov 19, 2026)
    CompanyProprio
    Official Websitepropriovision.com
    Washington HQ111 W John St, Suite 308, Seattle, WA 98119
    Other WA FootprintUniversity of Washington spinout; active clinical use and validation at UW Medicine / Harborview Medical Center
    Founded2016 (GeekWire 200, Fall 2026)
    Founders / LeadershipGabriel Jones (Co-Founder & CEO); Dr. Samuel R. Browd (Co-Founder & CMO); Dr. Joshua R. Smith (Co-Founder & CTO)
    StageSeries B / Growth
    Announced Funding$75M–$84M (GeekWire reported $84M to date in April 2025, including $43M Series B in 2023; Tracxn/PitchBook report $75M–$82M)
    Team Size50 (GeekWire 200, Fall 2026)
    Primary Ecosystem TiesUW spinout; UW Medicine / Harborview clinical deployment; Fall 2026 GeekWire 200; 2024 GeekWire Awards honoree; Seattle-area investors including Alan Frazier / East Seattle Partners

    Washington Footprint and Leadership

    Proprio is headquartered in Seattle's Lower Queen Anne / Uptown area at 111 W John St, Suite 308, Seattle, WA 98119, as listed in the footer of propriovision.com. The company spun out of the University of Washington in 2016 and retains deep academic and clinical roots across Seattle's medical research corridor.

    The founding leadership team profiled on Proprio's About page combines startup execution with UW medical and robotics faculty: Co-Founder and CEO Gabriel Jones leads the business alongside Co-Founder and Chief Medical Officer Dr. Samuel R. Browd, a pediatric neurosurgeon and UW faculty physician, and Co-Founder and Chief Technology Officer Dr. Joshua R. Smith, a UW professor specializing in robotics and sensor systems.

    Clinical validation has remained anchored locally at UW Medicine and Harborview Medical Center in Seattle. On the Fall 2026 GeekWire 200, Proprio is listed with 50 employees.

    • Seattle headquarters: Located at 111 W John St, Suite 308, Seattle, WA 98119, with 50 employees listed in Fall 2026.
    • UW academic spinout: Co-founded in 2016 by CEO Gabriel Jones alongside UW faculty Dr. Samuel R. Browd (neurosurgery) and Dr. Joshua R. Smith (robotics and sensors).
    • Local clinical validation: Actively deployed at UW Medicine / Harborview Medical Center, with UW spine surgeon Dr. Rick Bransford featured on the company's homepage.
    • Regional recognition: Listed on the Fall 2026 GeekWire 200 and recognized among finalists and honorees at the 2024 GeekWire Awards.
    Aerial view of the Greater Seattle and Bellevue Lake Washington technology corridor with Mount Rainier on the horizon
    Washington AI ecosystem context: Aerial view of the Greater Seattle and Bellevue Lake Washington technology corridor with Mount Rainier on the horizon.

    Products, Users, and Public Traction

    Proprio builds for spine and neurosurgeons, academic hospitals, ambulatory surgery centers (ASCs), and integrated health systems. In April 2025, GeekWire reported Proprio's second major FDA clearance for capturing real-time intraoperative measurements, noting active clinical deployments at UW Medicine and Duke Health.

    By November 2026, the Proprio homepage announced a third major FDA 510(k) clearance enabling 3D, dynamic, segmental anatomical viewing. Named surgeon endorsements on the site include Dr. Rick Bransford, Dr. Sig Berven, and Dr. Brett Rocos, alongside references to the HSG Research Collaboration.

    On the commercial and technology partner side, Proprio has partnered with LifeHealthcare for Southeast Asia distribution and works with Intel and HTC as technology partners. In 2025, the company also announced that Paradigm received a Fast Company 2025 World Changing Ideas Award.

    • Academic health system adoption: Clinical deployments reported at UW Medicine / Harborview Medical Center and Duke Health.
    • Three FDA 510(k) clearances: Progressed from initial surgical navigation clearance to real-time intraoperative measurements (April 2025) and dynamic 3D segmental viewing announced on its live homepage.
    • Distribution & hardware partners: Partnered with LifeHealthcare for Southeast Asia distribution and aligned with Intel and HTC on compute and optical/XR hardware.
    • External awards & clinical research: Honored with a Fast Company 2025 World Changing Ideas Award and linked to the HSG Research Collaboration.

    Funding, Stage, and Place in Washington's AI Landscape

    Proprio is a Series B / Growth company with $75M–$84M in total reported funding. In April 2025, GeekWire reported that Proprio had raised $84 million to date, following a $43 million Series B round in 2023 and an earlier $23 million Series A, while private-market trackers Tracxn and PitchBook record totals in the $75M–$82M range.

    Its investor syndicate spans deep-tech venture firms, corporate strategic backers, and Seattle life-science capital: DCVC (Data Collective), BOLD Capital Partners, Cota Capital, Intel Capital, HTC, Alan Frazier / East Seattle Partners, Hexagon VC, and Recode Health Ventures.

    Within Washington's broader AI cluster, Proprio sits at the intersection of University of Washington computer vision research, regulated medical devices, and physical-world sensor AI. Alongside Seattle-area clinical and telerobotic peers, it demonstrates how local academic spinouts have paired regulatory clearances with hospital partnerships to build durable medical hardware-software platforms.

    • Funding range preserved: Total disclosed capital spans $75M–$84M ($84M reported by GeekWire in April 2025; $75M–$82M in Tracxn/PitchBook).
    • Major milestones: Raised a $43M Series B in 2023 shortly after initial FDA clearance, building on an earlier $23M round.
    • Deep-tech & local backers: Investors include DCVC, BOLD Capital Partners, Cota Capital, Intel Capital, HTC, Hexagon VC, Recode Health Ventures, and Seattle's Alan Frazier / East Seattle Partners.
    • Ecosystem role: Anchor example of UW robotics and medical faculty commercializing regulated computer-vision AI inside Seattle's hospital network.

    Related Washington AI Profiles & Tygart Media Context

    Verified Primary Sources

  • AdaptX: Seattle AI Profile — Product, Footprint & Verified Record

    AdaptX: Seattle AI Profile — Product, Footprint & Verified Record

    Washington AI Companies Census · Verified Record (November 19, 2026)
    Sourced Baseline: As of November 19, 2026, AdaptX operates independently from Seattle with an active website at adaptx.com (displaying a 2025 copyright footer alongside SOC 2 Type II certification and active careers and contact pages) and 30 employees listed on the Fall 2026 GeekWire 200. Founded in 2016 as MDMetrix from clinical quality work at Seattle Children's Hospital, the company builds self-serve EMR analytics software for hospital surgical, emergency, and clinic leaders. AdaptX has raised over $20M in total venture funding, most recently an oversubscribed $10M round led by Cercano Management in November 2023.
    PROFILE BRIEF · HOUSE PDF & MARKDOWN TWIN
    AdaptX — Seattle AI Profile
    Download the formatted 2-page profile brief (PDF) or open the single-source Markdown twin for AdaptX. Every claim below links to its verified primary source.

    What AdaptX Builds

    AdaptX (formerly MDMetrix) builds a self-serve, AI-driven clinical performance management and clinical variation intelligence platform that connects directly to hospital electronic medical record (EMR) data. Rather than waiting on custom IT database queries, clinicians and hospital leaders use its Mission Control Center to evaluate care protocols, workflow bottlenecks, capacity, equity metrics, and revenue performance on demand.

    Specialty modules include OR Advisor, ED Advisor, and Clinic Advisor, covering operating rooms, emergency departments, and ambulatory clinics. On the AdaptX official website, the company highlights EMR-driven workflow improvement webinars on health equity and real-world data alongside clinical sustainability work such as its anesthesia greenhouse gas emissions case study.

    • Mission Control Center: Self-serve clinical analytics layer reading live hospital EMR records without requiring IT ticket queues.
    • Specialty operational modules: Includes OR Advisor, ED Advisor, and Clinic Advisor for surgical, emergency, and outpatient workflows.
    • Clinical variation & equity: Enables teams to measure protocol consistency, patient outcomes, and health equity across populations.
    • Sustainability analytics: Tracks anesthetic agent usage and clinical greenhouse gas emissions inside operating-room workflows.
    AdaptX — Verified Washington AI Snapshot
    Verified profile snapshot for AdaptX (Seattle, WA) as of November 19, 2026.
    FieldVerified Record (As of Nov 19, 2026)
    CompanyAdaptX (formerly MDMetrix)
    Official Websitehttps://www.adaptx.com/
    Washington HQSeattle, WA (98115 ZIP area; Seattle phone 206-620-0233)
    Other WA FootprintSpun out of clinical quality research initiated at Seattle Children's Hospital; backed by Seattle investors Cercano Management, Vulcan Capital, Founders' Co-op, and WRF Capital.
    Founded2016 (as MDMetrix; rebranded to AdaptX in July 2021)
    Founders / LeadershipDr. Dan Low (Co-Founder & Chief Medical Officer), Warren Ratliff (Chief Executive Officer)
    StageSeries B / Growth
    Announced FundingOver $20M ($10M oversubscribed round in Nov 2023 led by Cercano Management; $6M Series A in Jul 2021 led by Vulcan Capital)
    Team Size30 (Fall 2026 GeekWire 200)
    Primary Ecosystem TiesSeattle Children's Hospital spinout roots, Cercano Management, Vulcan Capital, Founders' Co-op, WRF Capital, GeekWire 200 (Fall 2026), 2024 GeekWire Awards finalist

    Washington Footprint and Leadership

    AdaptX operates in Seattle (associated with the 98115 ZIP area and listing Seattle telephone contact 206-620-0233 in its live site footer). The company traces directly to Seattle's pediatric health research community: pediatric anesthesiologist Dr. Dan Low at Seattle Children's Hospital co-founded the venture in 2016 as MDMetrix to give frontline clinicians direct access to real-world EMR data, as reported in GeekWire's July 2021 rebrand coverage.

    Healthcare technology executive Warren Ratliff serves as CEO, leading the company through its 2021 rebrand to AdaptX and its 2023 expansion round. Public records note an important freshness nuance as of November 2026: the live website still displays a 2025 copyright notice and GeekWire has not published a dedicated AdaptX-tagged story since November 2023, though the site remains active with careers and SOC 2 Type II disclosures and the Fall 2026 GeekWire 200 actively ranks AdaptX at 30 employees with no acquisition or shutdown. AdaptX is also distinct from unrelated UK 3D X-ray imaging company Adaptix and unrelated Massachusetts adaptive-sports nonprofit AdaptX (adaptx.org).

    • Seattle Children's Hospital origins: Co-founded in 2016 by pediatric anesthesiologist Dr. Dan Low (Co-Founder & Chief Medical Officer).
    • Executive leadership: Led by CEO Warren Ratliff alongside Seattle clinical and healthcare software staff.
    • Verified 2026 operating status: Active HTTP 200 commercial site (2025 footer notice), SOC 2 Type II certification, and 30 employees listed on the Fall 2026 GeekWire 200.
    • Name disambiguation: Unrelated to UK imaging firm Adaptix or Massachusetts adaptive-sports nonprofit AdaptX (adaptx.org).
    Aerial view of the Greater Seattle and Bellevue Lake Washington technology corridor with Mount Rainier on the horizon
    Washington AI ecosystem context: Aerial view of the Greater Seattle and Bellevue Lake Washington technology corridor with Mount Rainier on the horizon.

    Products, Users, and Public Traction

    AdaptX builds for clinical leaders, surgeons, anesthesiologists, emergency department directors, chief information officers, and hospital executives across academic medical centers, children's hospitals, multi-hospital health systems, and critical access hospitals. Named institutional relationships include Seattle Children's Hospital, strategic investor Memorial Hermann Health System, and Children's Minnesota—whose SVP and CIO David Lundal provides a named endorsement on the AdaptX homepage.

    In 2024, AdaptX was named a finalist for Health Innovation of the Year at the GeekWire Awards (a category won by Seattle clinical AI peer CalmWave). On its website, AdaptX reports customer outcomes including a hospital adding 150,000 operating-room minutes without staffing changes, an emergency department cutting left-without-being-seen (LWBS) rates by 50%, an interventional radiology team expanding revenue capacity by $8.5M, and an anesthesia team cutting greenhouse gas emissions by 90% in 90 days.

    • Named health-system ties: Publicly associated with Children's Minnesota, Seattle Children's Hospital, and Memorial Hermann Health System.
    • Regional healthcare recognition: Finalist for Health Innovation of the Year at the 2024 GeekWire Awards.
    • Company-reported operational metrics: Cites 150,000 additional OR minutes, 50% ED LWBS reduction, and $8.5M interventional radiology capacity expansion.
    • Reported sustainability impact: Case study details a 90% reduction in anesthesia greenhouse gas emissions within 90 days.

    Funding, Stage, and Place in Washington's AI Landscape

    AdaptX has raised over $20M in total venture financing. After rebranding from MDMetrix alongside a $6M Series A in July 2021 led by Vulcan Capital, the company raised an oversubscribed $10M round in November 2023 led by Cercano Management (the Vulcan spinout) with participation from Memorial Hermann Health System, Morningside Ventures, Founders' Co-op, Fortson VC, Star Equity, and WRF Capital. Earlier backers also include Arnold Venture Group and Alumni Ventures Group.

    Within Seattle's healthcare AI cluster, AdaptX represents a clinician-founded hospital operations specialist backed heavily by Pacific Northwest institutions—including Washington Research Foundation (WRF) Capital, Founders' Co-op, Vulcan Capital, and Cercano Management. Its Fall 2026 GeekWire 200 listing places it alongside Seattle clinical AI peers working inside operating rooms and hospital ICUs.

    • Cumulative financing: Over $20M raised, anchored by a $6M Series A (Jul 2021) and an oversubscribed $10M round (Nov 2023).
    • Deep Seattle investor base: Backed by Cercano Management, Vulcan Capital, Founders' Co-op, and WRF Capital.
    • Health-system strategic backing: Memorial Hermann Health System participated directly in its 2023 expansion round alongside institutional VCs.
    • Clinical AI niche: Complements Seattle's diagnostics and ICU monitoring startups by targeting self-serve EMR performance management.

    Related Washington AI Profiles & Tygart Media Context

    Verified Primary Sources

  • Mpathic: Bellevue AI Profile — Product, Footprint & Verified Record

    Mpathic: Bellevue AI Profile — Product, Footprint & Verified Record

    Washington AI Companies Census · Verified Record (November 19, 2026)
    Sourced Baseline: Mpathic (styled mpathic at mpathic.ai) is an active, independent Bellevue, Washington AI safety and conversation-intelligence company with 126 employees listed on the Fall 2026 GeekWire 200. Founded out of University of Washington clinical research lineage, the company expanded in 2025–2026 into clinician-led LLM red-teaming, human-data benchmarking, and its mPACT safety benchmark for high-risk conversations. Disclosed funding totals roughly $20.2M through a $15M 2025 round led by Foundry VC, while secondary trackers report a wider $12M–$34M range.
    PROFILE BRIEF · HOUSE PDF & MARKDOWN TWIN
    Mpathic — Bellevue AI Profile
    Download the formatted 2-page profile brief (PDF) or open the single-source Markdown twin for Mpathic. Every claim below links to its verified primary source.

    What Mpathic Builds

    Mpathic (styled mpathic at mpathic.ai) originally built AI and natural-language conversation intelligence software to measure empathy and communication quality in workplace and clinical interactions. Across 2025 and 2026, the company expanded that clinical evaluation engine directly into AI safety, clinician-led LLM red-teaming, and human-data benchmarking for foundational model developers and enterprise LLM application teams, as documented by GeekWire's 2026 clinical AI safety report.

    A centerpiece of that expansion is mPACT, a clinician-led safety benchmark launched in 2026 to measure how leading AI chatbots—including Claude, ChatGPT, and Gemini—respond in high-risk conversations involving suicide risk, eating disorders, youth mental health, and misinformation. As GeekWire reported on the benchmark launch, mPACT tests whether models merely avoid overt harm or meet clinical standards during sensitive exchanges.

    • Clinical AI safety and red-teaming: Applies behavioral and clinical science to test LLMs and reduce dangerous or clinically inadequate responses.
    • mPACT benchmark: Evaluates major chatbots (including Claude, ChatGPT, and Gemini) on suicide risk, eating disorders, youth mental health, and misinformation.
    • Conversation intelligence roots: Grew out of natural-language software analyzing empathy and communication dynamics in clinical and workplace settings.
    • Target buyers: Foundational AI model labs, enterprise LLM application teams, healthcare and digital health organizations, government AI policy evaluators, and enterprise coaching teams.
    Mpathic — Verified Washington AI Snapshot
    Verified profile snapshot for Mpathic (Bellevue, WA) as of November 19, 2026.
    FieldVerified Record (As of Nov 19, 2026)
    CompanyMpathic (styled mpathic)
    Official Websitempathic.ai (plain text; returns HTTP 403 WAF to automated checkers)
    Washington HQBellevue, WA (frequently described as Seattle-based or Seattle-area in regional reporting)
    Other WA FootprintUniversity of Washington clinical research lineage through co-founder Dr. Grin Lord
    Founded2021 (GeekWire 200 Fall 2026; 2020 launch origins from predecessor project Empathy Rocks per GeekWire 2026 coverage)
    Founders / LeadershipDr. Grin Lord (Co-founder & CEO); Nicolas (Nic) Bertagnolli (Co-founder & Chief AI Officer); Dr. Alison Cerezo (Chief Science Officer)
    StageGrowth / Series A ($15M 2025 round following $4M 2022 seed)
    Announced Funding~$20.2M disclosed ($5.2M through June 2022 seed + $15M in 2025 per GeekWire; secondary trackers report $12M–$34M)
    Team Size126 (GeekWire 200, Fall 2026)
    Primary Ecosystem TiesBellevue HQ; UW clinical research lineage; 2026 GeekWire Awards Startup of the Year finalist; 2023 Startup CEO finalist; PNW backers (Portland Seed Fund, Graham & Walker, First Row Partners); GeekWire 200 (Fall 2026)

    Washington Footprint and Leadership

    Mpathic is headquartered in Bellevue, Washington—within Greater Seattle, leading regional press to frequently refer to the company as Seattle-based—and appears on the Fall 2026 GeekWire 200 with 126 employees. Public records show a minor founding-year split: the GeekWire 200 lists 2021, whereas GeekWire's 2026 clinical safety coverage references 2020 origins tied to predecessor project Empathy Rocks.

    The company was co-founded by CEO Dr. Grin Lord—a board-certified clinical psychologist, former University of Washington research scientist, and 2023 GeekWire Awards Startup CEO of the Year finalist—together with Chief AI Officer Nicolas (Nic) Bertagnolli, who collaborated with Lord on Empathy Rocks. In 2026, GeekWire Tech Moves covered Mpathic's C-suite expansion, including Chief Science Officer Dr. Alison Cerezo leading clinical science and safety evaluation frameworks alongside additional 2026 executive hires.

    • Bellevue HQ and headcount: Headquartered in Bellevue, WA with 126 employees listed on the Fall 2026 GeekWire 200.
    • University of Washington lineage: Co-founder and CEO Dr. Grin Lord is a clinical psychologist and former UW research scientist.
    • Founding and science leadership: Co-founded with CAIO Nicolas Bertagnolli; expanded executive team in 2026 with Chief Science Officer Dr. Alison Cerezo.
    • Founding year record: Listed as 2021 on the Fall 2026 GeekWire 200, with 2020 origins traced to predecessor project Empathy Rocks.
    Aerial view of the Greater Seattle and Bellevue Lake Washington technology corridor with Mount Rainier on the horizon
    Washington AI ecosystem context: Aerial view of the Greater Seattle and Bellevue Lake Washington technology corridor with Mount Rainier on the horizon.

    Products, Users, and Public Traction

    Mpathic's public institutional traction bridges AI model labs, healthcare safety evaluation, and state-level policy oversight. Through indexed 2026 pages on mpathic.ai and regional reporting on its clinical AI safety expansion, Mpathic announced an agreement with the Utah Office of Artificial Intelligence Policy (OAIP) to independently evaluate healthcare AI safety alongside commercial LLM red-teaming and human-data benchmarking offerings. (Automated HTTP checks against mpathic.ai return HTTP 403 WAF bot protection, while live search indexing and five 2026 GeekWire reports confirm active independent operations.)

    Within the Pacific Northwest startup community, Mpathic was named one of five Startup of the Year finalists at the 2026 GeekWire Awards alongside ElastixAI, Dropzone AI, Dopl Technologies, and winner Loopr AI—building on Dr. Grin Lord's 2023 Startup CEO of the Year finalist recognition.

    • Government policy engagement: Entered an independent healthcare AI safety evaluation agreement with Utah's Office of Artificial Intelligence Policy (OAIP).
    • 2026 benchmark release: Publicly launched mPACT to score frontier AI chatbots on high-risk behavioral and mental health conversations.
    • Regional awards: Named a 2026 GeekWire Awards Startup of the Year finalist; CEO Dr. Grin Lord was a 2023 Startup CEO of the Year finalist.
    • Operational verification: Five 2026 GeekWire reports and live search-indexed mpathic.ai pages confirm ongoing independent operations despite WAF HTTP 403 blocking on automated fetches.

    Funding, Stage, and Place in Washington's AI Landscape

    Mpathic has disclosed roughly $20.2 million in venture capital across primary regional reporting: $5.2 million cumulative through a June 2022 $4 million seed round led by Next Frontier Capital, followed by a $15 million round in 2025 led by Foundry VC to scale clinical AI safety and conversational benchmarking, as discussed in Foundry VC's investment post. Secondary venture databases report a broader $12M–$34M range depending on round classification.

    Its investor syndicate includes Foundry VC, Next Frontier Capital, Illuminate Ventures, Full-Circle, WXR Fund, and three Pacific Northwest backers—Portland Seed Fund, Graham & Walker, and First Row Partners. Across Washington's AI ecosystem, Mpathic occupies a specialized human-clinical safety evaluation niche complementing inference-time safety peer Resect AI in Washougal, governance company GLACIS in Seattle, and behavioral-health AI peer Aria.

    • Disclosed funding trajectory: ~$20.2M disclosed across primary reporting ($5.2M through June 2022 seed plus $15M in 2025 led by Foundry VC); secondary trackers report $12M–$34M.
    • Lead and institutional backers: Foundry VC, Next Frontier Capital, Illuminate Ventures, Full-Circle, and WXR Fund.
    • Pacific Northwest investors: Portland Seed Fund, Graham & Walker, and First Row Partners.
    • Ecosystem differentiation: Combines UW clinical psychology roots with scalable LLM red-teaming and high-risk safety benchmarking.

    Related Washington AI Profiles & Tygart Media Context

    Verified Primary Sources

  • Ozette: Seattle AI Profile — Product, Footprint & Verified Record

    Ozette: Seattle AI Profile — Product, Footprint & Verified Record

    Washington AI Companies Census · Verified Record (November 19, 2026)
    Sourced Baseline: As of November 19, 2026, Ozette Technologies operates as an independent, privately held Seattle computational immunology company with 28 employees listed on the Fall 2026 GeekWire 200. Spun out of Fred Hutchinson Cancer Center in 2020 and incubated at AI2, the company builds the Resolve Analysis Platform, an Ozette MCP server for agentic cross-study querying, and lab/managed cytometry services for research use. Total disclosed venture funding stands at $32M across its Seed and $26M Series A rounds led by Madrona Venture Group.
    PROFILE BRIEF · HOUSE PDF & MARKDOWN TWIN
    Ozette — Seattle AI Profile
    Download the formatted 2-page profile brief (PDF) or open the single-source Markdown twin for Ozette. Every claim below links to its verified primary source.

    What Ozette Builds

    Ozette Technologies builds the Resolve Analysis Platform, an AI- and computationally-driven flow and spectral cytometry software suite that replaces subjective manual gating with 1-click, control-traceable single-cell immune phenotyping across studies and laboratory sites. As noted in the footer of the Ozette official website, its tools are built strictly for research use only and are not intended for clinical diagnostic use.

    Alongside self-serve software documented on the Ozette Pricing page—including a 7-day, 60-file trial and academic plans starting at $35/month billed annually—Ozette provides an Ozette MCP server that allows scientists to connect their own AI assistants to query and compare standardized, phenotyped immune cell populations across multiple clinical and preclinical studies. The company complements software with Ozette Lab (assay data generation) and Managed Cytometry Analysis services.

    • Resolve Analysis Platform: Self-serve flow and spectral cytometry analysis replacing manual gating with reproducible, control-traceable single-cell immune phenotyping.
    • Ozette MCP Server: Enables researchers' own AI agents to query and compare standardized immune cell populations across multi-site clinical and preclinical studies.
    • Ozette Lab & Managed Analysis: Hands-on assay data generation and managed cytometry analytics services for sponsors needing turnkey execution.
    • Research-Use Scope: Explicitly designated for research use only (not intended for diagnostic use), with accessible self-serve academic tiers starting at $35/month billed annually.
    Ozette — Verified Washington AI Snapshot
    Verified profile snapshot for Ozette (Seattle, WA) as of November 19, 2026.
    FieldVerified Record (As of Nov 19, 2026)
    CompanyOzette (Ozette Technologies)
    Official Websitehttps://www.ozette.com/
    Washington HQSeattle, WA (exact street address not listed on homepage footer)
    Other WA FootprintSpun out of Seattle's Fred Hutchinson Cancer Center and incubated at Allen Institute for AI (AI2 Incubator / AI House); local partnerships with Bloodworks Northwest, Umoja Biopharma, and Fred Hutch's CITN
    Founded2020 (Fred Hutch / AI2 spinout; GeekWire 200 Fall 2026 lists 2021)
    Founders / LeadershipDr. Greg Finak (Co-Founder & CEO), Dr. Raphael Gottardo (Co-Founder), Evan Greene (Co-Founder), Ali Ansary (Co-Founder & Former CEO)
    StageSeries A
    Announced Funding$32M ($6M Seed in late 2020/early 2021 + $26M Series A in July 2022)
    Team Size28 (GeekWire 200, Fall 2026)
    Primary Ecosystem TiesFred Hutchinson Cancer Center spinout, AI2 Incubator (AI House) alumnus, Madrona / M12 / Cercano / AI2 / Fred Hutch (investors), Bloodworks Northwest & Umoja Biopharma partnerships, GeekWire 200

    Washington Footprint and Leadership

    Ozette's origins sit squarely at the intersection of Seattle's biomedical and AI research institutions. The company spun out of Seattle's Fred Hutchinson Cancer Center in 2020 and was incubated at the Allen Institute for Artificial Intelligence (AI2 Incubator / AI House), where it continues to appear as an active, unacquired portfolio company on the AI House companies directory. While the GeekWire 200 lists a 2021 founding year (aligned with its early 2021 seed announcement) and 28 employees in Seattle, GeekWire spinout coverage dates the Fred Hutch and AI2 spinout to 2020.

    Ozette was co-founded by Dr. Greg Finak, Dr. Raphael Gottardo, Evan Greene, and Ali Ansary, as documented on the Ozette About page. Following a leadership transition, co-founder Dr. Greg Finak—a veteran computational cytometry and single-cell methods researcher and former Senior Scientist at Fred Hutchinson Cancer Center who previously served as CTO—now leads the company as CEO, succeeding co-founder and founding CEO Ali Ansary (an attending physician at UW Medicine and former AI2 Incubator Entrepreneur-in-Residence). Co-founders Dr. Raphael Gottardo (subsequently at Lausanne University) and Evan Greene also came from Fred Hutch.

    • Dual Seattle Institutional Pedigree: Spun out of Fred Hutchinson Cancer Center in 2020 and incubated inside Seattle's AI2 Incubator (AI House).
    • CEO Transition: Co-founder Dr. Greg Finak (former Fred Hutch Senior Scientist and Ozette's former CTO) serves as CEO, succeeding co-founder Ali Ansary.
    • Scientific Co-Founder Bench: Co-founded alongside Fred Hutch computational immunology researcher Dr. Raphael Gottardo, former Fred Hutch data scientist Evan Greene, and UW Medicine physician Ali Ansary.
    • Seattle Team Footprint: Tracked at 28 employees in Seattle on the Fall 2026 GeekWire 200, with open roles listed on the Ozette Careers page.
    Seattle waterfront startup incubator loft overlooking Puget Sound ferry lanes and the Olympic Mountains
    Washington AI ecosystem context: Seattle waterfront startup incubator loft overlooking Puget Sound ferry lanes and the Olympic Mountains.

    Products, Users, and Public Traction

    Ozette serves pharmaceutical and biotech clinical trial sponsors, contract research organizations (CROs), academic research centers, and flow cytometry core facilities seeking consistent cross-study immune profiling. In April 2026, Ozette expanded its global clinical-trial footprint through a strategic partnership with Cerba Research, pairing Cerba's global clinical-trial laboratory network with Ozette's 48-color spectral flow cytometry pan-immune profiling assay and AI analytics platform.

    That global CRO collaboration builds on an established base of Pacific Northwest life sciences partnerships. Earlier announced collaborators include Bloodworks Northwest / Bloodworks Bio (September 2023 cell-therapy partnership), Seattle-based Umoja Biopharma (July 2023 preclinical oncology partnership), and the Cancer Immunotherapy Trials Network (CITN) headquartered at Fred Hutchinson Cancer Center.

    • Cerba Research Global Alliance (April 2026): Combines Cerba's worldwide clinical-trial lab network with Ozette's 48-color spectral flow cytometry pan-immune profiling assay and AI analytics.
    • Seattle Life Sciences Collaborators: Publicly announced partnerships include Bloodworks Northwest / Bloodworks Bio (Sept 2023), Umoja Biopharma (July 2023), and Fred Hutch's CITN.
    • Self-Serve & Enterprise Reach: Bridges academic cytometry cores (via $35/month annual academic tiers and a 7-day 60-file trial) and global biopharma trial sponsors.
    • Agent-Ready Scientific Data: Introduced an Ozette MCP server so computational biologists can integrate standardized single-cell immune datasets directly into agentic research workflows.

    Funding, Stage, and Place in Washington's AI Landscape

    Ozette has raised $32M in total disclosed venture capital across two rounds led by Seattle's Madrona Venture Group: a $6M seed round (late 2020 / announced early 2021) and a $26M Series A in July 2022. Its investor roster spans major Pacific Northwest and life sciences institutions, including Madrona Venture Group, M12 (Microsoft's venture fund), Cercano Management (formerly Vulcan Capital), Allen Institute for Artificial Intelligence (AI2), Alexandria Venture Investments, Ascent Capital Advisors, Duke University, Fred Hutchinson Cancer Center, and OCV Partners.

    Within Washington's AI ecosystem, Ozette is a flagship bridge between Seattle's South Lake Union biotech cluster and its AI research institutions. Combining Fred Hutch immunology, AI2 incubation, Microsoft and Madrona capital, and recent clinical-trial commercialization with Cerba Research, the company demonstrates how domain-specific computational biology startups in Washington are pairing standardized assays with modern MCP-connected analytics.

    • $32M Total Disclosed Capital: Raised a $6M Seed (late 2020 / early 2021) and a $26M Series A (July 2022), both led by Madrona Venture Group.
    • Pacific Northwest Institutional Syndicate: Backed by Madrona, M12 (Microsoft), Cercano Management (formerly Vulcan Capital), AI2, and Fred Hutchinson Cancer Center.
    • Broader Life Sciences Investors: Cap table also includes Alexandria Venture Investments, Ascent Capital Advisors, Duke University, and OCV Partners.
    • Active Independent Trajectory: Remains an active Series A private company in Seattle expanding through CRO partnerships rather than pure wet-lab drug development.

    Related Washington AI Profiles & Tygart Media Context

    Verified Primary Sources

  • Outbound AI: Seattle AI Profile — Product, Footprint & Verified Record

    Outbound AI: Seattle AI Profile — Product, Footprint & Verified Record

    Washington AI Companies Census · Verified Record (November 19, 2026)
    Sourced Baseline: As of November 19, 2026, Outbound AI operates as an active, privately held Seattle company headquartered at 999 3rd Avenue with 35 employees tracked on the Fall 2026 GeekWire 200. Spun out of Madrona Venture Labs in March 2021, it develops HIPAA- and SOC-compliant conversational AI virtual agents for healthcare revenue cycle management phone workflows. Disclosed funding totals $23M across its initial 2021 raise and June 2023 $16M seed completion, with no Series A publicly announced through November 2026.
    PROFILE BRIEF · HOUSE PDF & MARKDOWN TWIN
    Outbound AI — Seattle AI Profile
    Download the formatted 2-page profile brief (PDF) or open the single-source Markdown twin for Outbound AI. Every claim below links to its verified primary source.

    What Outbound AI Builds

    Outbound AI builds Conversation AI Cloud, a HIPAA- and SOC-compliant conversational AI platform and portfolio of specialized virtual agents engineered for healthcare revenue cycle management (RCM). As detailed on the Outbound AI official website, its software automates repetitive payer-and-provider phone tasks that normally consume hours of medical billing staff time.

    Through dedicated operator interfaces including the PayerVA Console and Claims Work Console, Outbound AI's virtual agents conduct claims status checks, handle prior authorizations, and run insurance eligibility verifications across voice, text, and chat channels. The focus is narrow and operational: clearing administrative backlogs between healthcare providers, RCM service firms, and insurance payers.

    • Conversation AI Cloud: Healthcare-specific conversational AI platform built to automate administrative phone and messaging workflows across voice, text, and chat.
    • PayerVA Console & Claims Work Console: Specialized workflow consoles enabling billing teams to manage virtual agents running claims status checks, prior authorizations, and eligibility verification.
    • Healthcare Compliance Posture: Built for regulated medical billing environments with SOC and HIPAA compliance confirmed on the company's live website.
    • Target Buyers: Medical billing teams, physician practices, health systems, healthcare enterprises, and outsourced revenue cycle management partners.
    Outbound AI — Verified Washington AI Snapshot
    Verified profile snapshot for Outbound AI (Seattle, WA) as of November 19, 2026.
    FieldVerified Record (As of Nov 19, 2026)
    CompanyOutbound AI
    Official Websitehttps://outbound.ai/
    Washington HQSeattle, WA (999 3rd Avenue, Seattle, WA 98104)
    Other WA FootprintSpun out of Seattle's Madrona Venture Labs in March 2021; backed by Washington investors Madrona Venture Group, SpringRock Ventures, Ascend, Pack Ventures, and Tacoma Venture Fund
    Founded2021
    Founders / LeadershipStead Burwell (Co-Founder & CEO), Jonathan Wiggs (Co-Founder & CTO), Kshitij Moghe (Co-Founder), Justin Ith (Co-Founder), Ryan Greenhaw (Chief Revenue Officer)
    StageSeed / Series A
    Announced Funding$23M ($7M initial 2021 raise + $16M seed completion announced June 21, 2023)
    Team Size35 (GeekWire 200, Fall 2026)
    Primary Ecosystem TiesMadrona Venture Labs spinout, Madrona Venture Group & SpringRock Ventures (co-leads), Pack Ventures / Ascend / Tacoma Venture Fund, Microsoft Pegasus Program (Feb 2024), GeekWire 200 (Fall 2026)

    Washington Footprint and Leadership

    Outbound AI spun out of Seattle's Madrona Venture Labs in March 2021 and maintains its downtown Seattle headquarters at 999 3rd Avenue, Seattle, WA 98104 (confirmed on the Outbound AI official website and Outbound AI Contact page, phone 206-659-5165). The Fall 2026 GeekWire 200 tracks the company in Seattle at 35 employees.

    The startup was co-founded by healthcare technology executive Stead Burwell (CEO), veteran Seattle speech-and-communications engineer Jonathan Wiggs (CTO), Kshitij Moghe, and Justin Ith, with Ryan Greenhaw serving as Chief Revenue Officer. Wiggs brings more than 25 years in voice and software infrastructure, including an early leadership role at Seattle startup Jott, leading the R&D language model team at Nuance for Apple's initial Siri launch, and serving as VP of Engineering and Architecture at Seattle-based Avalara through its IPO.

    • Madrona Venture Labs Origin: Incubated and spun out of Seattle's Madrona Venture Labs in March 2021.
    • Downtown Seattle Office: Headquartered at 999 3rd Avenue, Seattle, WA 98104.
    • Deep Local Voice Engineering Roots: Co-founder & CTO Jonathan Wiggs previously worked at Jott, led Nuance's R&D language model team for Siri's initial launch, and served as VP of Engineering at Avalara.
    • Commercial Leadership: Co-founder Stead Burwell serves as CEO alongside Chief Revenue Officer Ryan Greenhaw overseeing enterprise provider and medical billing go-to-market.
    Aerial view of the Greater Seattle and Bellevue Lake Washington technology corridor with Mount Rainier on the horizon
    Washington AI ecosystem context: Aerial view of the Greater Seattle and Bellevue Lake Washington technology corridor with Mount Rainier on the horizon.

    Products, Users, and Public Traction

    Outbound AI sells into medical billing organizations, physician practices, health systems, and third-party revenue cycle management partners seeking to automate payer phone calls without expanding call-center headcount. On the Outbound AI official website, named customer testimonials cite Lincoln Popp, CEO of Acclara (noting alignment with Tegria's revenue cycle operations and Outbound AI's PayerVA Console), and Ryan Callahan, President of Orthos (referencing the Claims Work Console).

    In February 2024, Outbound AI was selected for the invite-only Microsoft for Startups Pegasus Program to accelerate enterprise healthcare distribution on Microsoft Azure, and on September 17, 2024, it announced winning the Healthcare AI Impact Award 2024. Public press cadence has been quieter since late 2024—the homepage Spotlight lists no newer announcements than September 2024—though the site carries an active 2026 copyright notice and GeekWire 200 Fall 2026 continues to track it as an active 35-person private company.

    • Named RCM Customers: Homepage testimonials feature Acclara (CEO Lincoln Popp, referencing Tegria's RCM operations and PayerVA Console) and Orthos (President Ryan Callahan, citing Claims Work Console).
    • Microsoft Azure Distribution Channel: Accepted into the invite-only Microsoft for Startups Pegasus Program in February 2024.
    • Industry Recognition: Announced winning the Healthcare AI Impact Award 2024 on September 17, 2024.
    • Verified 2026 Operating Status: Live 2026 website footer and Fall 2026 GeekWire 200 listing (35 employees) confirm ongoing independent operations despite a quiet public press calendar since late 2024.

    Funding, Stage, and Place in Washington's AI Landscape

    Outbound AI has raised $23M in total disclosed funding, comprising an initial $7M raise shortly after spinning out in March 2021 and a $16M seed financing completion announced on June 21, 2023 and reported by GeekWire. The June 2023 round was co-led by Seattle-based Madrona Venture Group and SpringRock Ventures, with participation from Epic Ventures, Ascend, Pack Ventures, Locke Capital, Tacoma Venture Fund, and KCRise Fund.

    With no Series A publicly disclosed through November 2026, Outbound AI sits in the Seed / Series A transition tier of Seattle's vertical AI sector. Its heavily Washington-anchored cap table—spanning Madrona, SpringRock, Ascend, Pack Ventures, and Tacoma Venture Fund—paired with speech-engineering leadership rooted in Seattle's Avalara and Jott lineage makes it a representative example of Pacific Northwest B2B voice AI applied to regulated healthcare administration.

    • $23M Total Disclosed Capital: Combines a $7M initial 2021 raise with the $16M seed completion announced in June 2023.
    • Washington-Led Syndicate: Co-led by Seattle's Madrona Venture Group and SpringRock Ventures alongside Ascend, Pack Ventures, and Tacoma Venture Fund.
    • Additional Institutional Backers: Epic Ventures, Locke Capital, and KCRise Fund also participated in its financing.
    • No Disclosed Series A Yet: Continues operating independently at 35 employees with no publicly announced follow-on equity round or acquisition through November 2026.

    Related Washington AI Profiles & Tygart Media Context

    Verified Primary Sources

  • RevealDx: Seattle AI Profile — Product, Footprint & Verified Record

    RevealDx: Seattle AI Profile — Product, Footprint & Verified Record

    Washington AI Companies Census · Verified Record (November 19, 2026)
    Sourced Baseline: As of November 19, 2026, RevealDx operates as an independent, privately held Seattle clinical AI company headquartered on Westlake Avenue North with approximately 9 employees tracked by PitchBook. Following U.S. FDA 510(k) clearance in February 2026 and an August 2026 US$3.4M Series A led by strategic partner 4DMedical (which holds a 10% stake and distribution rights), RevealDx is scaling commercial deployment of RevealAI-Lung across U.S., European, and Australian radiology markets. Cumulative venture funding ranges from ~$7.85M in PitchBook tracking to $12M+ across longer corporate history reported by GeekWire.
    PROFILE BRIEF · HOUSE PDF & MARKDOWN TWIN
    RevealDx — Seattle AI Profile
    Download the formatted 2-page profile brief (PDF) or open the single-source Markdown twin for RevealDx. Every claim below links to its verified primary source.

    What RevealDx Builds

    RevealDx develops RevealAI-Lung, a U.S. FDA 510(k)-cleared (K251769) computer-aided diagnostic (CADx) AI software application designed to analyze radiomic digital biomarkers on chest CT scans. Its clinical purpose, detailed on the RevealDx official website, is to assist radiologists in distinguishing benign pulmonary nodules from lung cancer earlier in the evaluation workflow.

    The software computes a continuous Malignancy Similarity Index (mSI™) score from 0 to 1—grouped into low, intermediate, and high risk bands. In the United States, RevealAI-Lung and its mSI™ score are cleared for evaluating incidentally-detected pulmonary nodules measuring 6–15 mm in diameter in patients aged 18 and older, and are explicitly not indicated for routine lung cancer screening in the U.S.

    • FDA 510(k)-Cleared CADx Software: Cleared under K251769 (announced February 2026) for incidentally-detected pulmonary nodules measuring 6–15 mm in adults 18 and older.
    • Malignancy Similarity Index (mSI™): Outputs a continuous 0-to-1 radiomics score categorized into low, intermediate, and high malignancy risk bands.
    • Multi-Region Regulatory Status: Holds European MDR certification (November 2025) and Australian TGA approval in addition to U.S. FDA 510(k) clearance.
    • Reimbursement Pathways: Supported in the U.S. by Medicare reimbursement CPT codes 0721T and 0722T.
    RevealDx — Verified Washington AI Snapshot
    Verified profile snapshot for RevealDx (Seattle, WA) as of November 19, 2026.
    FieldVerified Record (As of Nov 19, 2026)
    CompanyRevealDx
    Official Websitehttps://www.reveal-dx.com/
    Washington HQSeattle, WA (1800 Westlake Ave. N, Suite 104, Seattle, WA 98109)
    Other WA Footprint2026 GeekWire Awards Innovation Finalist; backed by Pacific Northwest angel networks Alliance of Angels and Frontier Angels
    Founded2021 (reorganized from Mindshare Medical, founded 2014)
    Founders / LeadershipChris Wood (CEO), Michael Calhoun (CTO), Dr. Ryan Brevard (Director of Clinical Programs), David Austin (VP of Sales)
    StageSeries A
    Announced Funding~$7.85M–$12M+ (includes Aug 2026 US$3.4M / A$4.9M Series A led by 4DMedical)
    Team Size~9 (PitchBook)
    Primary Ecosystem TiesSeattle Westlake HQ, Alliance of Angels & Frontier Angels (investors), 2026 GeekWire Awards Innovation Finalist

    Washington Footprint and Leadership

    RevealDx is headquartered along Lake Union at 1800 Westlake Ave. N, Suite 104, Seattle, WA 98109, with roughly 9 employees recorded by PitchBook. Its corporate history reflects two distinct milestones: CTO Michael Calhoun founded predecessor company Mindshare Medical in 2014 to develop the underlying lung-nodule radiomics technology, before the business was acquired and reorganized under Precision Medical Ventures in 2021 to operate as RevealDx under CEO Chris Wood, as outlined on the RevealDx Company page and in GeekWire's 2024 coverage.

    As regulatory clearances converted into active commercial rollout in late 2026, the company expanded its clinical and go-to-market bench. On November 2, 2026, RevealDx announced via its November 2026 leadership press release the appointments of Dr. Ryan Brevard (previously a Medical Advisor) as Director of Clinical Programs and medtech executive David Austin as Vice President of Sales.

    • Seattle Westlake Office: Operating from 1800 Westlake Ave. N, Suite 104, Seattle, WA 98109.
    • Corporate Continuity: Reorganized in 2021 under Precision Medical Ventures from predecessor Mindshare Medical, founded in 2014 by CTO Michael Calhoun.
    • Commercial & Clinical Expansion: Appointed Dr. Ryan Brevard (Director of Clinical Programs) and David Austin (VP of Sales) on November 2, 2026.
    • Local Ecosystem Recognition: Named an Innovation finalist at the 2026 GeekWire Awards and backed by Pacific Northwest angel groups Alliance of Angels and Frontier Angels.
    Aerial view of the Greater Seattle and Bellevue Lake Washington technology corridor with Mount Rainier on the horizon
    Washington AI ecosystem context: Aerial view of the Greater Seattle and Bellevue Lake Washington technology corridor with Mount Rainier on the horizon.

    Products, Users, and Public Traction

    RevealDx builds for radiologists, hospital lung nodule programs, health systems, and clinical imaging providers managing incidental CT findings. Rather than selling solely through a small direct sales team, the company has assembled clinical workflow integrations and distribution partnerships tracked in the RevealDx Press Room. Key partners include Azra AI (a May 2026 partnership integrating RevealAI-Lung nodule characterization into Azra's oncology workflow and incidental findings platform), technical integrations with Riverain Technologies and Fuji PACS, U.S. distributor Sirona, and global distributor 4DMedical.

    In clinical validation cited on the RevealDx official website, the company's clearance reader study on size-matched nodules smaller than 8 mm reported that ten radiologists improved diagnostic accuracy from an unaided AUC of 0.459 to 0.728 with mSI™ assistance, while retrospective validation across more than 1,500 diagnosed cases indicated mSI™ would have accelerated follow-up in 45% (range 33–59%) of guideline-deferred cancers. RevealDx is also exhibiting at RSNA 2026 (November 29–December 2, 2026, South Hall AI Showcase Booth 5930).

    • Global Distribution via 4DMedical: Under its August 2026 distribution agreement, 4DMedical holds exclusive distribution rights in Europe, Australia, and New Zealand and non-exclusive rights in the U.S.
    • Workflow & PACS Integrations: Partnered with Azra AI (May 2026) for incidental oncology workflow automation, alongside Riverain Technologies, Fuji PACS, and U.S. distributor Sirona.
    • Clearance Reader Study Metrics: RevealDx reports unaided radiologist accuracy on sub-8 mm nodules improved from AUC 0.459 to 0.728 with mSI™ support.
    • RSNA 2026 Presence: Scheduled to exhibit RevealAI-Lung at RSNA 2026 in Chicago from November 29 through December 2, 2026.

    Funding, Stage, and Place in Washington's AI Landscape

    In August 2026, Melbourne-based respiratory imaging company 4DMedical led RevealDx's Series A with a US$3.4M (A$4.9M) strategic investment. As disclosed in the 4DMedical partnership announcement, the financing gave 4DMedical a 10% fully diluted equity stake, one board seat, and a right of first negotiation over any future sale, while leaving RevealDx an independent, privately held Seattle corporation.

    Across data providers, total disclosed venture funding for RevealDx spans a range from approximately $7.85M in PitchBook records to $12M+ when incorporating cumulative historical funding reported by GeekWire across its earlier rounds (including a $4.2M raise covered by GeekWire in 2024). Backed by A-Level Capital, Alliance of Angels, Frontier Angels, Frost Data Capital, Life Science Angels, and 4DMedical, RevealDx stands out in Washington's health AI cohort for pairing regulated FDA 510(k) and EU MDR clearances with established CPT reimbursement codes on a lean capital base.

    • Strategic Series A Lead: 4DMedical led the August 2026 US$3.4M (A$4.9M) Series A, taking a 10% equity stake, a board seat, and a right of first negotiation on a future sale.
    • Cumulative Funding Range: Reported venture totals span ~$7.85M (PitchBook) to $12M+ (cumulative GeekWire history across predecessor and reorganized rounds).
    • Angel & Institutional Syndicate: Investors include 4DMedical, A-Level Capital, Alliance of Angels, Frontier Angels, Frost Data Capital, and Life Science Angels.
    • Regulated Clinical Differentiation: Combines FDA 510(k), EU MDR, TGA approval, and Medicare CPT codes 0721T/0722T within a compact Seattle medtech team.

    Related Washington AI Profiles & Tygart Media Context

    Verified Primary Sources

  • Avante: Seattle AI Profile — Product, Footprint & Verified Record

    Avante: Seattle AI Profile — Product, Footprint & Verified Record

    Washington AI Companies Census · Verified Record (November 19, 2026)
    Sourced Baseline: As of November 19, 2026, Avante (Avante Health, Inc.) operates as an independent Series A enterprise AI company headquartered at The Bullitt Center in Seattle, Washington (avante.ai, distinct from unrelated Houston benefits brokerage avantebenefits.com). Backed by $40M in total funding following its October 2026 $30M Series A, Avante deploys AI agents Ava and Carly for corporate Total Rewards teams and employees across 70 to 75+ companies.
    PROFILE BRIEF · HOUSE PDF & MARKDOWN TWIN
    Avante — Seattle AI Profile
    Download the formatted 2-page profile brief (PDF) or open the single-source Markdown twin for Avante. Every claim below links to its verified primary source.

    What Avante Builds

    Avante builds an enterprise AI platform and specialized AI agents designed for corporate employee benefits and Total Rewards organizations. At the core of avante.ai are the Avante Vault and Ontology, which structure employer plan documents, claims records, and vendor contracts into a single reference layer so HR teams are not stitching together answers from PDFs and spreadsheets.

    Two domain-specific AI agents run on top of that foundation: Ava, an operational agent built for benefits teams, and Carly, an employee-facing assistant available around the clock (GeekWire, Apr 9, 2026). Ahead of its October 2026 Series A announcement, Avante also released a beta version of expanded Ava Agents to handle deeper administrative and analytical workflows (GeekWire, Oct 27, 2026).

    • Ava for benefits teams: Compares vendor contracts against actual claims data, checks plan documents for errors, evaluates vendor ROI, automates renewal preparation, and drafts employee communications.
    • Carly for covered employees: Answers individualized employee and family questions about health plan coverage, eligibility, and benefits options 24/7.
    • Avante Vault and Ontology: Centralizes plan documentation and benefits program rules, with Avante reporting more than 9,400 plan documents stored across customer environments on avante.ai.
    Avante — Verified Washington AI Snapshot
    Verified profile snapshot for Avante (Seattle, WA) as of November 19, 2026.
    FieldVerified Record (As of Nov 19, 2026)
    CompanyAvante (Avante Health, Inc.; distinct from avantebenefits.com)
    Official Websitehttps://www.avante.ai/
    Washington HQSeattle, WA
    Other WA FootprintHeadquartered at The Bullitt Center, 1501 East Madison Street, Seattle, WA 98122 (per avante.ai privacy policy)
    Founded2023 (stealth emergence early 2024; public launch Apr 2025 per GeekWire, Oct 27, 2026)
    Founders / LeadershipRohan D'Souza (Co-founder & CEO), Carly Eckert, MD, PhD (Co-founder & Head of Innovation and Impact), Kabir Shahani (Co-founder & Executive Chairman)
    StageSeries A
    Announced Funding$40M total ($10M Seed led by Fuse in 2024 + $30M Series A led by Frist Cressey Ventures in Oct 2026 per GeekWire)
    Team Size64 employees (GeekWire 200, Fall 2026)
    Primary Ecosystem TiesFuse (Seattle-area VC); Amperity executive co-founder; GeekWire 200 (No. 156); 2026 GeekWire Awards AI Innovation finalist

    Washington Footprint and Leadership

    Operating legally as Avante Health, Inc., the company is headquartered in Seattle at The Bullitt Center, 1501 East Madison Street, Seattle, WA 98122, as listed in its privacy policy. Readers researching the company should note that Seattle's Avante at avante.ai is unrelated to Houston-based benefits brokerage Avante Benefits (avantebenefits.com).

    Avante was founded in 2023 by CEO Rohan D'Souza (former Chief Product Officer at healthcare automation company Olive AI), Head of Innovation and Impact Carly Eckert, MD, PhD (physician, epidemiologist, and former Olive AI EVP), and Executive Chairman Kabir Shahani (co-CEO of Seattle customer data platform Amperity), as detailed on its company page and in GeekWire. After emerging from stealth in early 2024 and launching publicly in April 2025, Avante grew to 64 employees and ranked No. 156 on the Fall 2026 GeekWire 200, while also earning a finalist nod for AI Innovation of the Year at the 2026 GeekWire Awards.

    Aerial view of the Greater Seattle and Bellevue Lake Washington technology corridor with Mount Rainier on the horizon
    Washington AI ecosystem context: Aerial view of the Greater Seattle and Bellevue Lake Washington technology corridor with Mount Rainier on the horizon.

    Products, Users, and Public Traction

    Avante sells to Chief People Officers, corporate Total Rewards and global benefits teams, and benefits advisory partners serving large employers confronting rising healthcare costs—noting in October 2026 that large employers project a median 9.2% healthcare cost increase for 2027 (GeekWire, Oct 27, 2026). Named enterprise customers disclosed across GeekWire and Avante's site include Samsung Semiconductor (profiled in a published Samsung Semiconductor case study), Real Chemistry, Zscaler, and News Corp. Advisory channel partners include Gallagher, OneDigital, Segal Benz, Howden, and USI Insurance Services.

    Across primary sources, Avante's reported customer base spans 70 to 75+ companies: GeekWire cited more than 70 customers on October 27, 2026, while avante.ai displays 75+ companies. Avante reports that its platform reaches more than 385,000 employees and family members and that bookings grew nearly fivefold over the prior year, though absolute revenue figures are not publicly disclosed.

    Funding, Stage, and Place in Washington's AI Landscape

    Avante has raised $40M in total disclosed equity funding, consisting of a $10M Seed round led by Seattle-area venture firm Fuse in 2024 and a $30M Series A announced on October 27, 2026 led by Frist Cressey Ventures with participation from Sorenson Capital, Hearst Ventures, Morgan Stanley Next Level Fund, and returning investor Fuse (GeekWire, Oct 27, 2026). Avante stated it will deploy the Series A capital toward international expansion and additional AI agent capabilities, and remains independent through November 2026.

    Within Washington's AI ecosystem, Avante bridges Seattle's enterprise SaaS leadership—via Amperity's Kabir Shahani and local seed lead Fuse—with healthcare-domain veterans addressing complex employer benefits administration. Competing alongside broader HR and benefits platforms such as Workday, ADP, Deel, and Rippling, Avante focuses specifically on claims-vs.-contract intelligence and employee coverage guidance.

    Related Washington AI Profiles & Tygart Media Context

    Verified Primary Sources

  • Synthesize Bio: Seattle AI Profile — Product, Footprint & Verified Record

    Synthesize Bio: Seattle AI Profile — Product, Footprint & Verified Record

    Washington AI Companies Census · Verified Record (November 19, 2026)
    Sourced Baseline: As of November 19, 2026, Synthesize Bio operates as an independent, Seed-stage Seattle computational biology startup at synthesize.bio. Spun out of Fred Hutchinson Cancer Center in 2023 by co-founders Jeff Leek, PhD, and Robert Bradley, PhD, the company raised a $10M Seed round led by Madrona Venture Group in September 2025 and builds generative genomics foundation models (GEM-1) and the VERDICT platform to simulate human biology and forecast clinical trial outcomes for biopharma teams.
    PROFILE BRIEF · HOUSE PDF & MARKDOWN TWIN
    Synthesize Bio — Seattle AI Profile
    Download the formatted 2-page profile brief (PDF) or open the single-source Markdown twin for Synthesize Bio. Every claim below links to its verified primary source.

    What Synthesize Bio Builds

    Synthesize Bio develops generative genomics foundation models and clinical prediction software—positioned on its official website as "Virtual Human Models for Clinical Prediction"—to simulate hypothetical biology experiments before wet-lab studies or human trials are executed. Its core GEM model family (introduced publicly with GEM-1 and an accompanying September 2025 bioRxiv preprint) learns from harmonized human RNA-sequencing and single-cell data to predict gene expression responses across healthy and diseased cells and tissues (GeekWire, Sep 16, 2025).

    On top of those generative expression models, Synthesize Bio builds VERDICT, a platform that uses simulated human biology to evaluate drug candidates and forecast clinical trial outcomes—covering statistical significance, treatment-arm direction, effect size, and serious adverse events. As co-founder Robert Bradley told GeekWire, biopharma and academic scientists regularly face costly go-or-no-go decisions with incomplete information; Synthesize Bio's goal is to give teams computational feedback earlier in R&D rather than replacing wet-lab science.

    • GEM generative expression models: Trained on company-stated datasets spanning 800,000 bulk RNA-seq samples, 400M single cells, 22,300 unique perturbation contexts, 50+ human tissues, and 40+ therapeutic areas (synthesize.bio).
    • VERDICT clinical trial prediction: Incorporates 12,418 labelled clinical trials to forecast endpoint success, treatment direction, effect size, and serious adverse event risk for asset evaluation and trial design.
    • Retrospective validation benchmark: On synthesize.bio, Synthesize Bio reports that across 1,717 held-out later clinical trials, trials VERDICT predicted as successful achieved a 70% observed success rate compared with 52% across all evaluated trials (a 35% relative gain in meeting at least one significant primary endpoint).
    Synthesize Bio — Verified Washington AI Snapshot
    Verified profile snapshot for Synthesize Bio (Seattle, WA) as of November 19, 2026.
    FieldVerified Record (As of Nov 19, 2026)
    CompanySynthesize Bio
    Official Websitehttps://www.synthesize.bio/
    Washington HQSeattle, WA
    Other WA FootprintFred Hutchinson Cancer Center spinout; backed by Seattle's Madrona Venture Group and AI2 Incubator
    Founded2023 (GeekWire, Sep 16, 2025)
    Founders / LeadershipJeff Leek, PhD (Co-Founder & CEO), Robert Bradley, PhD (Co-Founder & SAB Chair), Ariel Brumbaugh (Senior Director of Business Development)
    StageSeed
    Announced Funding$10M Seed round (Sep 2025; led by Madrona Venture Group with AI2 Incubator, Sahsen Ventures, Inner Loop Capital, and Point Field Partners)
    Team Size16 employees (GeekWire, Sep 16, 2025); live site highlights 11 PhD scientists plus co-founders
    Primary Ecosystem TiesFred Hutchinson Cancer Center; Madrona Venture Group; AI2 Incubator / AI House; 2026 GeekWire Awards AI Innovation finalist

    Washington Footprint and Leadership

    Synthesize Bio is headquartered in Seattle, Washington, originating as a 2023 spinout from Fred Hutchinson Cancer Center (GeekWire, Sep 16, 2025). The company maintains its canonical web presence at https://www.synthesize.bio/ (its company page details the founding team and scientific staff, while an alternate .com address returns HTTP 403). No public street address is disclosed on the live site.

    Co-founder and CEO Jeff Leek, PhD served as Chief Data Officer and J. Orin Edson Foundation Endowed Chair at Fred Hutch, was named a TIME100 AI 2025 honoree, received the Presidents' Award for top statistician under 40, and created open-source genomics software downloaded over 1.4 million times (synthesize.bio). Co-founder and Scientific Advisory Board Chair Robert Bradley, PhD directed Fred Hutch's Translational Data Science Integrated Research Center, held the McIlwain Family Endowed Chair, conducted research on how faulty RNA splicing drives cancer, and previously co-founded Codify Therapeutics. In October 2025, Synthesize Bio hired Ariel Brumbaugh from Gladstone Institutes as Senior Director of Business Development (GeekWire Tech Moves, Oct 23, 2025). GeekWire reported a 16-person team at the September 2025 launch, and the live site highlights 11 PhD scientists with backgrounds at BMS, J&J, Recursion, Novo, Pathos, Freenome, and Genentech.

    Aerial view of the Greater Seattle and Bellevue Lake Washington technology corridor with Mount Rainier on the horizon
    Washington AI ecosystem context: Aerial view of the Greater Seattle and Bellevue Lake Washington technology corridor with Mount Rainier on the horizon.

    Products, Users, and Public Traction

    Synthesize Bio builds for biopharmaceutical drug development teams, clinical trial designers, and biotech asset and investment evaluators seeking earlier signals on whether therapeutic candidates that pass safety checks are likely to demonstrate clinical efficacy. The company maintains a Trust Center and states a SOC 2 compliance posture on synthesize.bio.

    Specific biopharma customer names, partnership contracts, and commercial revenue figures are not publicly disclosed. Public ecosystem validation includes selection as a finalist for AI Innovation of the Year at the 2026 GeekWire Awards (alongside Avante, ConverzAI, Envive AI, and Spangle AI) and presenting to national venture investors at Seattle's AI House Demo Day on Pier 70 in September 2026.

    Funding, Stage, and Place in Washington's AI Landscape

    Synthesize Bio is a Seed-stage startup that emerged from stealth in September 2025 with a $10M Seed round led by Seattle's Madrona Venture Group (GeekWire, Sep 16, 2025), joined by AI2 Incubator, Sahsen Ventures, Inner Loop Capital, and Point Field Partners. No subsequent Series A round or acquisition has been publicly disclosed through November 2026.

    Within Seattle's life-sciences AI corridor, Synthesize Bio sits directly at the bridge between the city's biomedical research institutions and its applied AI investor base. Alongside Fred Hutch, the University of Washington's Institute for Protein Design, and local biotech AI peers applying foundation models to cell biology and automated lab execution, Synthesize Bio represents a Seattle thesis centered on computational biology models trained on large-scale public and clinical genomics datasets.

    Related Washington AI Profiles & Tygart Media Context

    Verified Primary Sources

  • CalmWave: Seattle AI Profile — Product, Footprint & Verified Record

    CalmWave: Seattle AI Profile — Product, Footprint & Verified Record

    Washington AI Companies Census · Verified Record (November 19, 2026)
    Sourced Baseline: As of November 19, 2026, CalmWave operates as an independent, Seed-stage Seattle health-tech startup at calmwave.com (with calmwave.ai redirecting to the canonical .com domain). Spun out of Seattle's AI2 Incubator in 2022 by founder and CEO Ophir Ronen, the company has evolved from ICU alarm-fatigue software into a hospital-wide clinical data foundation (Tessera) backed by approximately $13.6M in disclosed cumulative venture capital, including a $5.25M round in November 2024 and a $4.4M seed extension in June 2025.
    PROFILE BRIEF · HOUSE PDF & MARKDOWN TWIN
    CalmWave — Seattle AI Profile
    Download the formatted 2-page profile brief (PDF) or open the single-source Markdown twin for CalmWave. Every claim below links to its verified primary source.

    What CalmWave Builds

    CalmWave builds a hospital clinical data foundation centered on its Transparent AI approach and Tessera platform, designed to ingest, normalize, and analyze real-time clinical signals across acute-care facilities. On its official website, CalmWave focuses on unifying data streams from bedside patient monitors, connected medical devices, alarm logs, medications, and electronic health records (EHRs) across multiple vendors without replacing existing clinical hardware or middleware.

    The platform reflects a documented expansion from CalmWave's initial intensive care unit focus. Early product releases—described in GeekWire's November 2024 and June 2025 reporting as "Quiet ICU" and "Calm ICU"—targeted the non-actionable bedside monitor alerts that the company states represent 80% to 99% of ICU alarms. On its current site, CalmWave frames that same longitudinal clinical signal ingestion as a system-wide data foundation for tuning vital-sign alarm limits, surfacing earlier signs of patient physiologic deterioration, and supporting Joint Commission alarm-management compliance.

    • Multi-vendor data ingestion: Captures real-time streams from bedside monitors, medical devices, alarm systems, and EHRs across existing hospital middleware.
    • Structure and enrichment: Standardizes and fuses vital signs, medications, alarms, and patient context into longitudinal records for individual patients and full wards.
    • Explainable clinical recommendations: Applies data science and transparent AI models to filter non-actionable alerts, recommend patient-specific vital-sign thresholds, and flag physiologic deterioration earlier, with SOC 2 Type II and HIPAA compliance stated on calmwave.com.
    CalmWave — Verified Washington AI Snapshot
    Verified profile snapshot for CalmWave (Seattle, WA) as of November 19, 2026.
    FieldVerified Record (As of Nov 19, 2026)
    CompanyCalmWave
    Official Websitehttps://calmwave.com/
    Washington HQSeattle, WA (2801 Alaskan Wy, Seattle, WA 98121)
    Other WA FootprintPier 70 waterfront / AI House hub; spun out of Seattle's Allen Institute for AI (AI2) Incubator
    Founded2022 (AI2 Incubator spinout; GeekWire 200 Fall 2026)
    Founders / LeadershipOphir Ronen (Founder & CEO)
    StageSeed
    Announced Funding~$13.6M cumulative venture capital disclosed, including $5.25M (Nov 2024, headlined at $5.2M in GeekWire) and $4.4M seed extension (Jun 2025) backed by Third Prime, Bonfire Ventures, Catalyst by Wellstar, Silver Circle, Tau Ventures, Hike Ventures, Rebellion, Impulsum Ventures, and AI2 Incubator
    Team Size23 employees (GeekWire 200, Fall 2026)
    Primary Ecosystem TiesAI2 Incubator / AI House; 2023 & 2024 GeekWire Awards winner; GeekWire 200 index

    Washington Footprint and Leadership

    CalmWave is headquartered on Seattle's waterfront at 2801 Alaskan Wy, Seattle, WA 98121, as listed in its Privacy Policy—co-located at Pier 70 alongside Seattle's AI House community. The company spun out of the Allen Institute for AI (AI2) Incubator in 2022 and remains listed as an active, independent incubator company on the AI House Companies directory.

    Founder and CEO Ophir Ronen is a repeat Seattle entrepreneur who previously founded Event Enrichment HQ, a local startup focused on filtering and routing IT incident alerts that was acquired by PagerDuty in 2015 (GeekWire, Jun 26, 2025). That alert-noise background directly shaped CalmWave's shift from IT operations to clinical monitoring. On the Fall 2026 GeekWire 200 startup index, CalmWave is listed in Seattle with 23 employees, following regional recognition including UX Design of the Year at the 2023 GeekWire Awards and Health Innovation of the Year at the 2024 GeekWire Awards.

    Seattle waterfront startup incubator loft overlooking Puget Sound ferry lanes and the Olympic Mountains
    Washington AI ecosystem context: Seattle waterfront startup incubator loft overlooking Puget Sound ferry lanes and the Olympic Mountains.

    Products, Users, and Public Traction

    CalmWave builds for hospital and health-system stakeholders spanning nurses, physicians, clinical engineering and biomedical teams, hospital leadership and operations, and risk and quality management groups. Its canonical domain is https://calmwave.com/ (its earlier calmwave.ai address redirects cleanly to the .com site), offering platform documentation for Transparent AI and Tessera alongside role-specific clinical use cases and demo requests.

    The company's most detailed public deployment is with Wellstar Health System (including Wellstar Cobb Medical Center), whose venture arm Catalyst by Wellstar is also a backer. Executive quotes on calmwave.com feature Dr. Pranav Jain (Chief Health Information Officer, Wellstar Health System), Dr. Jody Hughes (Chief Medical Officer, Wellstar Cobb Medical Center), Ryan Sanders (AVP, Clinical Engineering, Wellstar Health System), and John D. Cooper and Dr. Lori Westphal of Catalyst by Wellstar. Earlier November 2024 GeekWire coverage also noted hospital-network partnerships with Premier, Inc. and Partners Co-op. Total hospital count and revenue figures are not publicly disclosed.

    Published clinical metrics differ slightly by deployment context and should be read with their source boundaries intact. In a six-week Wellstar Health System pilot case study reported by GeekWire in June 2025, CalmWave reported reducing technical bedside alarms by more than 50% (lowering clinician interruptions from 68 to 36 per hour and daily bedside monitor alarms from 1,635 to 873), cutting patient alarm exposure by 10 hours per stay, and alerting nurses to deterioration up to 15 minutes faster. Across its broader homepage benchmarks, calmwave.com states a 47% non-actionable alarm reduction within weeks, 10 fewer hours of alarm exposure per patient stay, and 2 to 4 hours of RN time reclaimed per shift.

    Funding, Stage, and Place in Washington's AI Landscape

    CalmWave is a Seed-stage company with approximately $13.6M in cumulative venture capital disclosed across its incubator and seed financings. Key reported tranches include a $5.25M round announced in November 2024 (headlined at $5.2M by GeekWire) led by Third Prime with participation from Catalyst by Wellstar, Silver Circle, Rebellion, Impulsum Ventures, and returning backers Bonfire Ventures, Tau Ventures, and Hike Ventures, followed by a $4.4M seed extension in June 2025 led by Third Prime, Bonfire Ventures, Catalyst by Wellstar, and Silver Circle alongside earlier AI2 Incubator backing. No Series A financing or acquisition has been publicly announced through November 2026.

    Within Washington's applied healthcare AI cluster, CalmWave illustrates how local AI2 Incubator spinouts are moving down-stack from single-department point tools into hospital-wide data infrastructure. Rather than deploying opaque generative chat interfaces inside acute care, CalmWave pairs multi-vendor physiologic telemetry with explainable threshold recommendations—putting it in the same clinical-safety tier of Seattle health AI startups working directly on bedside monitoring and longitudinal patient signals.

    Related Washington AI Profiles & Tygart Media Context

    Verified Primary Sources

  • Polybiomics: Seattle AI Profile — Product, Footprint & Verified Record

    Polybiomics: Seattle AI Profile — Product, Footprint & Verified Record

    Washington AI Companies Census · Verified Record (November 19, 2026)
    Sourced Baseline: As of November 19, 2026, Polybiomics (Polybiomics Inc.) is an active, independent life-science AI startup with Washington ties spanning Plug and Play Seattle's Batch 2 cohort and a 2025 Washington Competes Grant listing in Kirkland. Its website lists 10 team members and a 4-member Scientific Advisory Board, while founding year and institutional venture funding remain undisclosed.
    PROFILE BRIEF · HOUSE PDF & MARKDOWN TWIN
    Polybiomics — Seattle AI Profile
    Download the formatted 2-page profile brief (PDF) or open the single-source Markdown twin for Polybiomics. Every claim below links to its verified primary source.

    What Polybiomics Builds

    Polybiomics (Polybiomics Inc.) develops a modular, integrated live-cell analysis platform designed to observe dynamic cellular behavior without destroying samples. On polybiomics.com, the company organizes its architecture into three components: a proprietary Bioinstrument and Consumable, its PolyData™ and Analytics software layer, and an AI engine for actionable intelligence.

    Conventional cell assays often rely on destructive endpoint measurements or capture only one parameter at a time. Polybiomics states that its proprietary polysensing consumable generates multi-parameter matrix data during imaging of a single live-cell sample, simultaneously and continuously tracking multiple phenotypes and biological functions without disturbing the cells or their 3D microenvironments. PolyData™ integrates those multimodal streams while the company's AI engine extracts predictive patterns intended to shorten discovery timelines, lower experimental costs, and improve reproducibility.

    In GeekWire's September 19, 2025 coverage of Plug and Play Seattle's second cohort, the accelerator described Polybiomics as having 'developed a live cell analysis platform that streamlines drug discovery' by turning complex multimodal data into clear insights while keeping biological samples intact.

    • Bioinstrument and Consumable: proprietary polysensing consumable capturing multi-parameter matrix signals during non-destructive live-cell imaging.
    • PolyData™ and Analytics: software layer integrating and interpreting multimodal, time-series live-cell datasets.
    • AI Engine: extracts patterns from dynamic cell behavior across 3D environments for drug discovery, biomanufacturing, and clinical workflows.
    Polybiomics — Verified Washington AI Snapshot
    Verified profile snapshot for Polybiomics (Seattle, WA) as of November 19, 2026.
    FieldVerified Record (As of Nov 19, 2026)
    CompanyPolybiomics (Polybiomics Inc.)
    Official Websitehttps://www.polybiomics.com/
    Washington HQSeattle, WA (Plug & Play Seattle Batch 2); also indexed in Kirkland, WA (WA Competes Grant) with earlier Berkeley, CA directory listings
    Other WA FootprintKirkland, WA; UW CoMotion Labs (Seattle) and SNBL Global Gateway (Everett) via Plug & Play Seattle
    FoundedNot publicly disclosed
    Founders / LeadershipMandana Veiseh, PhD (Founder, President & CSTO); Bahram Bahrami, PhD (Co-founder & CEO)
    StageAccelerator / Grant-Backed
    Announced FundingNot publicly disclosed (2025 Washington Competes Grant recipient; program awards up to $25,000)
    Team Size10 listed on official website (2 executives + 8 team members; excludes 10 advisors)
    Primary Ecosystem TiesPlug and Play Seattle Batch 2 (Sept 2025); Life Science Washington Competes Grant (April 2025); Fred Hutch / UW research roots

    Washington Footprint and Leadership

    Polybiomics has a multi-city West Coast footprint that requires careful reading across public directories. In September 2025, GeekWire listed 'Polybiomics, Seattle' as one of six local Seattle-area startups selected for Plug and Play Seattle's Batch 2 accelerator, a 12-week program running through mid-December 2025 primarily at the University of Washington's CoMotion Labs with additional space at SNBL Global Gateway in Everett. Earlier in 2025 (April 8, 2025), Life Science Washington Institute and the Washington State Department of Commerce announced Polybiomics Inc.—indexed in Kirkland, WA—as a recipient of a Washington Competes Grant. Meanwhile, earlier Bay Area biotech and accelerator directories have listed Polybiomics in Berkeley, California, reflecting founder research ties at Lawrence Berkeley National Laboratory, and polybiomics.com itself omits a street address or city.

    The company is led by Founder, President, and Chief Scientific and Technology Officer Mandana Veiseh, PhD and Co-founder and CEO Bahram Bahrami, PhD. Both founders share Pacific Northwest translational oncology research roots at Fred Hutchinson Cancer Research Center and the University of Washington, and Veiseh previously held research and technical roles at Lawrence Berkeley National Laboratory and Xerox-PARC. On polybiomics.com, Polybiomics lists eight additional team members (David Stumbo, PhD; Shahab S. Bahaei, PhD; Therese Choquette, PhD; Kayla Solomon, DMD; Bob Smith-McCollum, MBA; Ava Aslanpour, BE; Navya Mangipudi, BE; and Haro Hartounian, PhD), four Scientific Advisory Board members—including National Academy members Mina J. Bissell, PhD, Kurt Petersen, PhD, and Ron W. Davis, PhD, plus Rick Horwitz, PhD—and six business and legal advisors.

    Aerial view of the Greater Seattle and Bellevue Lake Washington technology corridor with Mount Rainier on the horizon
    Washington AI ecosystem context: Aerial view of the Greater Seattle and Bellevue Lake Washington technology corridor with Mount Rainier on the horizon.

    Products, Users, and Public Traction

    Polybiomics positions its platform for four life-science buyer groups: academic researchers, pharmaceutical drug discovery teams, biomanufacturing operators, and clinical workflow teams. By consolidating multi-parameter monitoring onto a single non-destructive sample from early discovery through late-stage development, the company aims to cut reagent waste and improve experimental reproducibility.

    Public commercial disclosures remain early-stage. Polybiomics has not published named pharmaceutical customers, instrument pricing, shipment counts, or peer-reviewed clinical deployments tied to the commercial product on polybiomics.com. Readers inspecting the site should also note that while its technical messaging aligns with its late-2025 Seattle accelerator profile, the website footer still displays a 2024 copyright notice (© 2024 POLYBIOMICS INC.) and routes inquiries through operations@polybiomics.com.

    • Target markets: academic research labs, pharmaceutical drug discovery, biomanufacturing, and clinical workflows.
    • Listed personnel: 10 core leadership and team members, 4 Scientific Advisory Board members (3 National Academy members), and 6 advisors.
    • Public gaps: founding year, commercial customer roster, and instrument pricing are not publicly disclosed.

    Funding, Stage, and Place in Washington's AI Landscape

    No institutional venture capital round or cumulative equity raise has been publicly announced by Polybiomics through November 2026. Its verified Washington financial and program milestones are non-dilutive and accelerator-based: selection for the Washington Competes Grant (a state program administered by Life Science Washington Institute and the Washington Department of Commerce awarding up to $25,000 to early-stage Washington life-science companies) in April 2025, followed by selection for Plug and Play Seattle Batch 2 in September 2025.

    Within Washington's biotech-AI cluster, Polybiomics sits at the instrumentation-and-wet-lab boundary alongside Seattle AI drug-discovery peers like Clockwork Bio. Rather than relying solely on public molecular databases or pure in-silico models, Polybiomics pairs proprietary physical biosensing hardware and consumables with multimodal AI analysis—a capital-intensive, defensible approach closely aligned with Seattle's Fred Hutch, UW, and Eastside life-science research talent.

    Related Washington AI Profiles & Tygart Media Context

    Verified Primary Sources